EP4494157A1 — Drug delivery device with electronics
Assigned to Norton Waterford Ltd · Expires 2025-01-22 · 1y expired
What this patent protects
A system may include an inhaler (100) and an external device (904). The inhaler may include a main body (104) having a mouthpiece (106), medicament, and an electronics module (120). The electronics module may include a processor (1026), memory (1030), a sensor (1027), a switch (1…
USPTO Abstract
A system may include an inhaler (100) and an external device (904). The inhaler may include a main body (104) having a mouthpiece (106), medicament, and an electronics module (120). The electronics module may include a processor (1026), memory (1030), a sensor (1027), a switch (130), and a wireless communication circuit (129). The processor may generate a dose record in response to a dosing event. The dosing event may be an actuation of the switch (130) or measurements received by the sensor (1027). The processor (1026) may store the first dose record in memory and cause the wireless communication circuit (129) to transmit advertising data. The advertising data may include a dose record indicator that indicates that one or more dose records are stored in the memory (1030) of the electronics module (120). The external device (904) may receive the advertising data and determine, based on the advertising data, whether the inhaler (100) includes records not stored on the external device.
Drugs covered by this patent
- Cutivate (FLUTICASONE PROPIONATE) · Teva Pharm
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.